Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Transgene, Tasly ink HBV, oncology agreements
September 2018
SHARING OPTIONS:

STRASBOURG, France—Drug candidates T601 and T101 are the focus of a series of new agreements between Transgene and Tasly Biopharmaceuticals Co. Ltd. signed in the third quarter of 2018. The two companies developed oncolytic immunotherapy T601 and hepatitis B virus (HBV) vaccine T101, which incorporate Transgene's TG6002 and TG1050 immunotherapy technologies respectively, through their joint venture in China. Under the terms of the agreements, Transgene will receive Tasly shares valued at $48 million, and will transfer its 50-percent share in their joint venture to Tasly, making the latter the full owner of the joint venture and the greater China patent rights to T601. Transgene is also assigning T101 patent rights in greater China to Tasly. All transactions are subject to customary closing conditions, including completion of the administrative transfer of assets contributed by Transgene to Tasly.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2018 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.